Jennifer Buchholz
Family · Harvard, MANPI 1427424696
Payments from drug & device makers
Across 590 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$597
- Lilly USA, LLC$570
- Bayer$541
- plus $5K from 38 others
What the payments were for
- Food & beverage$11,333100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,335 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 91 | $116,142 |
| OzempicSemaglutide | 59 | $79,836 |
| TrulicityDulaglutide | 54 | $76,214 |
| JardianceEmpagliflozin | 51 | $75,610 |
| EliquisApixaban | 63 | $68,441 |
| NuplazidPimavanserin Tartrate | 12 | $58,042 |
| JanuviaSitagliptin Phosphate | 36 | $47,364 |
| MounjaroTirzepatide | 35 | $46,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $35,104 |
| XareltoRivaroxaban | 29 | $30,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $30,421 |
| MyrbetriqMirabegron | 26 | $22,912 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $20,096 |
| InvokanaCanagliflozin | 15 | $13,887 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,607 | $146,563127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $570 | $122,38789 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $363 | $86,99663 claims |
| Novo NordiskOzempic | $1,207 | $79,83659 claims |
| PfizerEliquis | $487 | $68,44163 claims |
| MerckJanuvia, Belsomra | $360 | $56,51957 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $78 | $55,20041 claims |
| Johnson & JohnsonXarelto, Invokana | $506 | $44,82744 claims |
| Astellas Pharma US IncMyrbetriq | $159 | $22,91226 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $119 | $5,74913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Harvard
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.